Latest Amgen Stories

In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012 by Amgen over PR Newswire, we are advised by the company that the third paragraph now includes additional safety information. The complete, corrected release follows: Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or...

THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness...

THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall...

THOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (U.S.) Food and Drug Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members of the FDA panel charged with implementing a pathway for biosimilars to establish approval standards that advance patient safety and promote confidence in...

WASHINGTON and THOUSAND OAKS, Calif., May 9, 2012 /PRNewswire/ -- The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options(TM), a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (CDC), the Open to Options program is ready to provide professional counselors who help...

LOS ANGELES, May 8, 2012 /PRNewswire/ -- Roger and Ann Worthington, longtime supporters of mesothelioma patients and their families, generously donated $25,000 to The Pacific Meso Center (PMC). "Their donation honors the mesothelioma patients and their families who joined other cancer survivors in the Amgen Breakaway from Cancer Walk at the Dana Point Grand Prix of Cycling on Sunday, May 6th 2012," said Clare Cameron, executive director of PMC. The walk took place at 3:35 p.m. prior...

REDWOOD CITY, Calif., May 7, 2012 /PRNewswire/ -- An executive management team made up of early biotech pioneers who helped build America's biotherapeutics industry today announced the creation of Coherus BioSciences, dedicated to providing patients around the world with greater access to high-quality biosimilar therapies. (Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO) The new company was launched concurrently with the announcement of a strategic partnership with...

THOUSAND OAKS, Calif., May 4, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Baird Growth Stock conference on Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, Ill., beginning at 8:20 a.m. Central Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. About Amgen Amgen discovers, develops, manufactures...

THOUSAND OAKS, Calif., May 3, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 37th Annual Healthcare Conference on Tuesday, May 8, 2012, at the InterContinental Hotel, Boston, Mass., beginning at 9:20 a.m. Eastern Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. About AmgenAmgen discovers,...

THOUSAND OAKS, Calif., May 1, 2012 /PRNewswire/ -- Amgen today announced that four individuals who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer® Champions. They will be honored at the seventh consecutive edition of the Amgen Tour of California as part of Amgen's Breakaway from Cancer initiative. The Amgen Tour of California is America's largest and most prestigious road cycling stage race, which will...